STOCK TITAN

bioAffinity hits 235 CyPath Lung tests in October 2026

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reported 235 CyPath Lung tests performed in October 2026, its highest monthly volume, up 29% from October 2025. October testing volume was approximately 45% of all tests performed in Q3 2026. The company said use increased among established and newly ordering physicians and that it expanded its sales team.

CyPath Lung analyzes sputum cell populations using flow cytometry and proprietary AI to help assess the likelihood of lung cancer; it is designed to complement imaging and clinical assessment, not serve as a sole diagnostic tool. A published clinical trial among high-risk patients with small indeterminate nodules less than 20 millimeters reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
CyPath Lung tests performed 235 tests October 2026; highest monthly volume reported
Year-over-year change in tests 29% increase October 2026 compared with October 2025
Share of Q3 testing volume Approximately 45% October 2026 tests compared with all tests performed in Q3 2026
Sensitivity 92% Published clinical trial in high-risk patients with small indeterminate lung nodules less than 20 millimeters
Specificity 87% Published clinical trial in high-risk patients with small indeterminate lung nodules less than 20 millimeters
Accuracy 88% Published clinical trial in high-risk patients with small indeterminate lung nodules less than 20 millimeters
Negative predictive value 99% Published clinical trial in high-risk patients with small indeterminate lung nodules less than 20 millimeters
flow cytometry technical
"using flow cytometry and proprietary AI"
A laboratory method that uses lasers and sensors to count and analyze individual cells or tiny particles as they flow past a detector, like a high‑speed supermarket scanner that reads barcodes on each item. Investors care because flow cytometry is widely used in drug development, diagnostics and manufacturing quality control; demand for the instruments, reagents and services can signal progress in clinical programs, recurring revenue streams and adoption of new therapies or tests.
negative predictive value (NPV) medical
"99% negative predictive value (NPV)"
Laboratory Developed Test (LDT) regulatory
"marketed as a Laboratory Developed Test (LDT)"
A laboratory developed test (LDT) is a medical diagnostic test that a single clinical laboratory designs, validates and uses in-house rather than buying from a commercial manufacturer. For investors, LDTs matter because they can drive a lab’s revenue and growth more quickly than mass-market products but also carry unique risks around accuracy, reimbursement and changing regulatory rules — think of a local bakery’s custom recipe versus a factory-made packaged product.
sensitivity medical
"92% sensitivity"
specificity medical
"87% specificity"
Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CyPath Lung tests did BIAF perform in October 2026?

bioAffinity reported 235 tests performed in October 2026, a 29% increase compared with October 2025. That volume was approximately 45% of all tests performed in Q3 2026.

What clinical performance did the CyPath Lung trial report?

A published trial in high-risk patients with small indeterminate lung nodules less than 20 millimeters reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value for detecting lung cancer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001712762 0001712762 2026-11-11 2026-11-11 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2026-11-11 2026-11-11 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2026-11-11 2026-11-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 11, 2026

 

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

 

(210) 698-5334

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class   Trading Symbols   Name of each exchange on which registered

Common Stock, par value $0.007 per share

 

 

 

BIAF

 

 

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

         
Warrants to purchase Common Stock   BIAFW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01. Other Events.

 

On November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
  Description
99.1   Press Release issued by bioAffinity Technologies, Inc., dated November 11, 2026
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 -2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 17, 2026 BIOAFFINITY TECHNOLOGIES, INC.
   
  By: /s/ Maria Zannes
  Name: Maria Zannes
  Title: President and Chief Executive Officer

 

 -3-

 

 

 

Exhibit 99.1

 

bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

 

October testing volume equals approximately 45% of all tests performed in the previous quarter

 

SAN ANTONIO, Texas – November 11, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test.

 

The October results demonstrate continued growth in test utilization by both established and newly ordering physicians. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026.

 

“October’s testing volume reflects our efforts to expand the commercial reach of CyPath Lung,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “In addition to expanding physician adoption and strengthening relationships with existing customers, we are taking additional steps to expand the reach of CyPath Lung and set the stage for long-term growth. We have expanded our sales team. We are working with patient advocacy organizations to strengthen our connections within the lung cancer community, and we are seeing significant advances in our R&D to apply our proprietary technology platform to asthma and COPD.”

 

CyPath Lung is a noninvasive test that analyzes cell populations in sputum using flow cytometry and proprietary AI to help physicians assess the likelihood of lung cancer by analyzing the lung microenvironment. The test is designed to complement existing imaging and clinical assessment and provide physicians with additional information when determining appropriate next steps for patients.

 

bioAffinity continues to advance its commercial strategy through direct physician engagement, distribution relationships and opportunities within government healthcare systems. The Company is focused on increasing awareness and utilization of CyPath Lung among pulmonologists and other healthcare providers while building on its growing base of ordering physicians and repeat testing activity.

 

 

 

 

About CyPath Lung

 

CyPath Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath Lung incorporates proprietary antibodies and a novel fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV may help inform physician decision-making when evaluating whether further invasive procedures are warranted. CyPath Lung is marketed as a Laboratory Developed Test (LDT), is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.

 

About bioAffinity Technologies, Inc.

 

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent may identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially, including the Company’s ability to sustain physician demand and convert commercial efforts into reimbursable testing and revenue; variability in monthly testing volume; reimbursement coverage, payment rates, denials and collection delays; the ability to establish and maintain distribution relationships and obtain government healthcare business; and the possibility that research will not establish the clinical performance or utility needed for new applications or lead to commercially viable products. Historical testing volume does not establish future growth, revenue or profitability. Additional risks and uncertainties are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on forward-looking statements. These statements speak only as of the date of this release, and the Company undertakes no obligation to update them, except as required by applicable law.

 

Contact

 

bioAffinity Technologies

Julie Anne Overton

Director of Communications

investors@bioaffinitytech.com

 

-2-

 

Filing Exhibits & Attachments

5 documents

Keep reading